Image

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Testing BMF-219 for certain blood cancers and genetic mutations.

Recruiting
18 years and older
All
Phase 1
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study tests a new drug called BMF-219, which is a covalent menin inhibitor. Menin is a protein that can affect how certain cancers grow. The drug is for adults with specific blood cancers: AML (Acute Myeloid Leukemia), ALL (Acute Lymphocytic Leukemia), DLBCL (Diffuse Large B-cell Lymphoma), MM (Multiple Myeloma), and CLL/SLL (Chronic Lymphocytic Lymphoma/Small Lymphocytic Lymphoma). The study is in Phase 1, meaning it's the first time this drug is being tested in humans to find the best dose and check for safety.

  • The study involves taking an oral drug and requires several visits to the study site.
  • Participants must be adults with specific mutations or who have tried other treatments without success.
  • There may be risks, such as side effects, and participants must use birth control during the study and for 90 days after.

Participants cannot join if they have certain other diseases, infections, or have used similar treatments before. This study helps researchers understand if BMF-219 can help treat these blood cancers and what side effects it might have.

Print
Study details
    Acute Myeloid Leukemia
    Acute Lymphoblastic Leukemia
    Acute Mixed-Phenotype Leukemia
    Cancer
    Refractory
    Progression
    Diffuse Large B Cell Lymphoma
    Multiple Myeloma
    Lymphoma
    Lymphoma
    Non-Hodgkin
    Myeloma
    Plasma-Cell
    Myelomatosis
    Plasma Cell Myeloma
    Chronic Lymphocytic Leukemia
    Small Lymphocytic Lymphoma

NCT05153330

Biomea Fusion Inc.

13 December 2024

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.